SELLAS Life Sciences (SLS) Cost of Revenue (2013 - 2022)
SELLAS Life Sciences (SLS) posted quarterly Cost of Revenue of $100000.0 for Q1 2022, little changed year-over-year from $100000.0 in Q1 2021, and little changed quarter-over-quarter from $100000.0 in Q2 2021.
SELLAS Life Sciences (SLS) Cost of Revenue (2013 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Cost of Revenue for 5 consecutive years, with $100000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Cost of Revenue changed 0.0% year-over-year to $100000.0; the TTM figure through Dec 2022 stood at $100000.0 (down 50.0% YoY), while the FY2022 annual figure was $100000.0, down 50.0% from the prior year.
- Cost of Revenue held at $100000.0 in Q1 2022 per SLS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $100000.0 in Q1 2021 and bottomed at $100000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Jun 30, 2015 | 468,000.00 |
| Jun 30, 2015 | 468,000.00 |
| Mar 31, 2015 | 393,000.00 |
| Mar 31, 2015 | 393,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Sep 30, 2014 | 247,000.00 |
| Sep 30, 2014 | 247,000.00 |
| Jun 30, 2014 | 347,000.00 |
| Jun 30, 2014 | 347,000.00 |
| Mar 31, 2014 | 331,000.00 |
| Mar 31, 2014 | 331,000.00 |
| Dec 31, 2013 | 262,000.00 |
| Dec 31, 2013 | 262,000.00 |